2019 Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

April 2019 | 136 pages | ID: 25FEADF7B58EN
VPAResearch

Abstracts

The global clinical trial report- “2019 Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Anaplastic Large Cell Lymphoma (ALCL). It presents in-depth analysis of Anaplastic Large Cell Lymphoma (ALCL) clinical trials across markets and companies. The research work is for providing complete understanding into trends in Anaplastic Large Cell Lymphoma (ALCL).

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Anaplastic Large Cell Lymphoma (ALCL) clinical trials by-

• Current Trial Status
• Type of the trial
• Sponsor Type
• Enrollment Trends
• Region
• Countries
• Trial Phase

The report also identifies the potential drug candidates under development for treatment of Anaplastic Large Cell Lymphoma (ALCL)

The research work is prepared through extensive and continuous research on Anaplastic Large Cell Lymphoma (ALCL) trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:

• All major trials from 2010 to 2019 and planned trials are included in the report scope.
• Drug candidates currently being researched for administering Anaplastic Large Cell Lymphoma (ALCL) patients are identified
• The report includes panorama of Anaplastic Large Cell Lymphoma (ALCL) clinical trials across the globe
• Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
• Companies and universities focusing on Anaplastic Large Cell Lymphoma (ALCL) clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
• Average Enrollment number, insights into enrollment trends, company wise enrollment are included
• Both interventional and observational studies are analyzed
• News and latest developments for the past one year are presented in the report

Contents

1. TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2. EXECUTIVE SUMMARY

2.1 Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
  2.2.1 Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials by Region
  2.2.2 Average Enrollment of Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials
  2.2.3 Companies participating in Trials
  2.2.4 Drugs under Study for Anaplastic Large Cell Lymphoma (ALCL) Treatment, 2019

3. REGION WISE ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) CLINICAL TRIALS

3.1 Asia Pacific Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials by Country
3.2 Europe Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials by Country
3.3 North America Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials by Country
3.4 Middle East and Africa Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials by Country
3.5 South and Central America Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials by Country

4. ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) CLINICAL TRIAL TRENDS

4.1 Start Year wise Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials
4.2 Phase wise Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials
4.3 Trial Status wise Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials
4.4 Trial Type wise Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials

5. ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) AVERAGE ENROLLMENT TRENDS

5.1 Average Enrollment in Anaplastic Large Cell Lymphoma (ALCL) Trials by Year
5.2 Average Enrollment in Anaplastic Large Cell Lymphoma (ALCL) Trials by Phase
5.3 Average Enrollment in Anaplastic Large Cell Lymphoma (ALCL) Trials by Status
5.4 Average Enrollment in Anaplastic Large Cell Lymphoma (ALCL) Trials by Type of Trial

6. COMPANIES PARTICIPATING IN ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) CLINICAL TRIALS

6.1 Anaplastic Large Cell Lymphoma (ALCL) Trials by Sponsor Type
6.2 Anaplastic Large Cell Lymphoma (ALCL) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 TRIAL SNAPSHOTS- PHASE, TYPE, TITLE, LOCATION, START YEAR, COMPLETION YEAR, RECRUITMENT STATUS, ENROLLMENT, PARTICIPATING COUNTRIES, TRIAL LOCATIONS, COMPANY, DRUGS AND OTHER DETAILS

7.1 Anaplastic Large Cell Lymphoma (ALCL) Trials- Phase
7.2 Anaplastic Large Cell Lymphoma (ALCL) Trials- Phase
7.3 Anaplastic Large Cell Lymphoma (ALCL) Trials- Phase
7.4 Anaplastic Large Cell Lymphoma (ALCL) Trials- Phase

8. APPENDIX

8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List Of Figures

LIST OF FIGURES

Figure 1: Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials and Enrolment
Figure 5: Europe – Country wise Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials and Enrolment
Figure 7: North America – Country wise Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials and Enrolment
Figure 9: Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials by Phase
Figure 10: Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials by Trial Status
Figure 11: Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials by Type
Figure 12: Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials by Sponsor Type
Figure 13: Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials by Leading Sponsors
Figure 14: Anaplastic Large Cell Lymphoma (ALCL) Average Enrollment by Phase
Figure 15: Anaplastic Large Cell Lymphoma (ALCL) Average Enrollment by Trial Status
Figure 16: Anaplastic Large Cell Lymphoma (ALCL) Average Enrollment by Type
Figure 17: Anaplastic Large Cell Lymphoma (ALCL)- Average Enrolment by Type of Sponsors
Figure 18: Anaplastic Large Cell Lymphoma (ALCL)- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List Of Tables

LIST OF TABLES

Table 1: Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials and Enrolment
Table 5: Europe – Country wise Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials and Enrolment
Table 7: North America – Country wise Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Anaplastic Large Cell Lymphoma (ALCL) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Anaplastic Large Cell Lymphoma (ALCL) Average Enrollment by Phase
Table 15: Anaplastic Large Cell Lymphoma (ALCL) Average Enrollment by Trial Status
Table 16: Anaplastic Large Cell Lymphoma (ALCL) Average Enrollment by Type
Table 17: Anaplastic Large Cell Lymphoma (ALCL)- Average Enrolment by Type of Sponsors
Table 18: Anaplastic Large Cell Lymphoma (ALCL)- Enrolment by Leading Sponsors